JP2022551467A - 鎮痛性及び麻酔性ペプチド及び他の薬剤 - Google Patents

鎮痛性及び麻酔性ペプチド及び他の薬剤 Download PDF

Info

Publication number
JP2022551467A
JP2022551467A JP2022521298A JP2022521298A JP2022551467A JP 2022551467 A JP2022551467 A JP 2022551467A JP 2022521298 A JP2022521298 A JP 2022521298A JP 2022521298 A JP2022521298 A JP 2022521298A JP 2022551467 A JP2022551467 A JP 2022551467A
Authority
JP
Japan
Prior art keywords
peptide
pain
injection
animals
peptides
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022521298A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022551467A5 (enExample
Inventor
バッターチャルジー，アリンダム
Original Assignee
ザ リサーチ ファウンデイション フォー ザ ステイト ユニバーシティー オブ ニューヨーク
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ザ リサーチ ファウンデイション フォー ザ ステイト ユニバーシティー オブ ニューヨーク filed Critical ザ リサーチ ファウンデイション フォー ザ ステイト ユニバーシティー オブ ニューヨーク
Publication of JP2022551467A publication Critical patent/JP2022551467A/ja
Publication of JP2022551467A5 publication Critical patent/JP2022551467A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A61P23/02—Local anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Anesthesiology (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2022521298A 2019-10-10 2020-10-12 鎮痛性及び麻酔性ペプチド及び他の薬剤 Pending JP2022551467A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962913512P 2019-10-10 2019-10-10
US62/913,512 2019-10-10
PCT/US2020/055289 WO2021072392A1 (en) 2019-10-10 2020-10-12 Analgesic and anesthetic peptides and other agents

Publications (2)

Publication Number Publication Date
JP2022551467A true JP2022551467A (ja) 2022-12-09
JP2022551467A5 JP2022551467A5 (enExample) 2023-09-22

Family

ID=75437541

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022521298A Pending JP2022551467A (ja) 2019-10-10 2020-10-12 鎮痛性及び麻酔性ペプチド及び他の薬剤

Country Status (10)

Country Link
US (1) US20240294571A1 (enExample)
EP (1) EP4051690A4 (enExample)
JP (1) JP2022551467A (enExample)
KR (1) KR20220079651A (enExample)
CN (1) CN114829372A (enExample)
AU (1) AU2020364246A1 (enExample)
BR (1) BR112022006862A2 (enExample)
CA (1) CA3157686A1 (enExample)
IL (1) IL292102A (enExample)
WO (1) WO2021072392A1 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025029752A2 (en) * 2023-07-28 2025-02-06 Gate Science, Inc. Methods and systems for pain management and testing thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012019192A2 (en) * 2010-08-06 2012-02-09 Mount Sinai School Of Medicine Cell-permeable molecules as growth factor receptor antagonists
WO2019118779A2 (en) * 2017-12-13 2019-06-20 The Research Foundation For The State University Of New York Peptides and other agents for treating pain and increasing pain sensitivity

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU733719B2 (en) * 1996-10-23 2001-05-24 Trustees Of The University Of Pennsylvania, The Improved vaccines
IL136076A0 (en) * 1997-11-26 2001-05-20 Zymogenetics Inc Mammalian cytokin-like polypeptide -10
KR20030069989A (ko) * 2000-09-08 2003-08-27 다이이찌 산토리 파마 가부시키가이샤 심부전 치료제
PL2211873T3 (pl) * 2007-10-22 2013-01-31 Amorphical Ltd Stabilny amorficzny węglan wapnia wchodzący w skład fosforylowanych aminokwasów
CN112218650A (zh) * 2018-01-15 2021-01-12 单侧Ip私人有限公司 肽及其用途

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012019192A2 (en) * 2010-08-06 2012-02-09 Mount Sinai School Of Medicine Cell-permeable molecules as growth factor receptor antagonists
WO2019118779A2 (en) * 2017-12-13 2019-06-20 The Research Foundation For The State University Of New York Peptides and other agents for treating pain and increasing pain sensitivity

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
BREMNES, T., ET AL.: ""A Region from the Medium Chain Adaptor Subunit (μ) Recognizes Leucine- and Tyrosine-based Sorting", THE JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 273, no. 15, JPN6024033985, 1998, pages 8638 - 8645, ISSN: 0005554435 *
GURURAJ, S., ET AL.: ""Protein kinase A-induced internalization of Slack channels from the neuronal membrane occurs by ada", J. BIOL. CHEM., vol. 292, no. 47, JPN6024033986, 2017, pages 19304 - 19314, XP055816515, ISSN: 0005554436, DOI: 10.1074/jbc.M117.804716 *
KELLY, B.T., ET AL.: ""A structural explanation for the binding of endocytic dileucine motifs by the AP2 complex."", NATURE, vol. 456, JPN6024033984, 2008, pages 976 - 981, ISSN: 0005554434 *

Also Published As

Publication number Publication date
CN114829372A (zh) 2022-07-29
CA3157686A1 (en) 2021-04-15
AU2020364246A1 (en) 2022-05-12
US20240294571A1 (en) 2024-09-05
KR20220079651A (ko) 2022-06-13
IL292102A (en) 2022-06-01
WO2021072392A1 (en) 2021-04-15
BR112022006862A2 (pt) 2022-07-05
EP4051690A1 (en) 2022-09-07
EP4051690A4 (en) 2024-01-17

Similar Documents

Publication Publication Date Title
Powell et al. Inhibiting endocytosis in CGRP+ nociceptors attenuates inflammatory pain-like behavior
US12077610B2 (en) Peptides and other agents for treating pain and increasing pain sensitivity
CN117701566A (zh) 结合至人类肌养蛋白前体mRNA的外显子51的反义寡核苷酸
US11365413B2 (en) Inhibition of poly(A) binding protein and the treatment of pain
CN105848720A (zh) 用于诱导葡萄糖摄取的方法
Han et al. Neurovascular protection conferred by 2-BFI treatment during rat cerebral ischemia
Liang et al. miR-328-3p affects axial length via multiple routes and anti-miR-328-3p possesses a potential to control myopia progression
CN110564842A (zh) 细胞色素酶cyp26a1在制备治疗神经病理性疼痛的药物中的应用
JP2022551467A (ja) 鎮痛性及び麻酔性ペプチド及び他の薬剤
KR20130027016A (ko) 포유류와 인간 세포에서 ｈｉｖ 복제를 억제하는 방법
Arai et al. Neuronal Ca2+‐dependent activator protein 1 (NCDAP1) induces neuronal cell death by activating p53 pathway following traumatic brain injury
EP4494649A1 (en) Peptides for use in the treatment of axonal damage in diabetes
Lai et al. CtBP1 is essential for epigenetic silencing of μ-opioid receptor genes in the dorsal root ganglion in spinal nerve ligation-induced neuropathic pain
Wang et al. OTULIN of exosomes derived from Schwann cells promotes peripheral nerve injury repair by regulating macrophage polarization via deubiquitination of ERBB2
JP5835699B2 (ja) 瘢痕化抑制と線維症治療を目的とする組成物と方法
US20240173376A1 (en) Trem-1 inhibitors for the treatment of marfan syndrome
EA036003B1 (ru) Способ лечения оптической нейропатии с применением двухцепочечной рнк к casp2
KR102213878B1 (ko) Pat4를 포함하는 만성통증 질환 예방, 개선 또는 치료용 조성물
US20220133849A1 (en) Compositions and methods for the treatment of smooth muscle dysfunction
US20250064846A1 (en) Treatment and prevention of trigeminal neuralgia
WO2026056985A1 (zh) 抑郁症的治疗方法和药物组合物
Powell II Nociceptor Endocytosis Regulates Inflammatory Pain
JP2020026397A (ja) ＴｒｋＢアンタゴニストを含む医薬組成物
JPWO2012011486A1 (ja) 神経ペプチドを用いた神経因性疼痛軽減薬剤ならびに抗うつ薬剤

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230913

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230913

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20240816

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240828

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20241024

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20250319